Phentermine News and Research

RSS
Phentermine is a drug that decreases your appetite.
Weight loss pill Qnexa wins panel vote and awaits approval

Weight loss pill Qnexa wins panel vote and awaits approval

FDA panel votes in favor of earlier rejected anti-obesity drug Qnexa

FDA panel votes in favor of earlier rejected anti-obesity drug Qnexa

FDA EMDAC recommends approval of VIVUS' Qnexa for obesity

FDA EMDAC recommends approval of VIVUS' Qnexa for obesity

FDA to review rejected weight loss drug Qnexa

FDA to review rejected weight loss drug Qnexa

FDA approves Lannett's supplemental ANDA for Phentermine HCl to treat obesity

FDA approves Lannett's supplemental ANDA for Phentermine HCl to treat obesity

FDA EMDAC schedules to review VIVUS' Qnexa NDA for treatment of obesity

FDA EMDAC schedules to review VIVUS' Qnexa NDA for treatment of obesity

VIVUS announces results of Qnexa clinical study on cardiometabolic disease

VIVUS announces results of Qnexa clinical study on cardiometabolic disease

FDA accepts VIVUS' Qnexa NDA for filing and review

FDA accepts VIVUS' Qnexa NDA for filing and review

Multiple abstracts on QNEXA presented at 47th EASD

Multiple abstracts on QNEXA presented at 47th EASD

VIVUS announces additional data from phase 3 QNEXA studies on obesity

VIVUS announces additional data from phase 3 QNEXA studies on obesity

FDA approves Lannett's ANDA for Phentermine Resin Extended-Release Capsules

FDA approves Lannett's ANDA for Phentermine Resin Extended-Release Capsules

VIVUS to present topiramate exposure, birth defect data at IEC

VIVUS to present topiramate exposure, birth defect data at IEC

Multiple abstracts on QNEXA long-term clinical study to be presented at ADA 2011

Multiple abstracts on QNEXA long-term clinical study to be presented at ADA 2011

The Lancet publishes VIVUS 56-week QNEXA study results in obesity

The Lancet publishes VIVUS 56-week QNEXA study results in obesity

Investigational drug effective for patients with obesity

Investigational drug effective for patients with obesity

New weight loss pill - combination of two existing drugs

New weight loss pill - combination of two existing drugs

FDA approves ANDA for phentermine HCl 37.5 mg tablets

FDA approves ANDA for phentermine HCl 37.5 mg tablets

VIVUS holds End-of-Review meeting with FDA for QNEXA NDA

VIVUS holds End-of-Review meeting with FDA for QNEXA NDA

VIVUS seeks marketing approval of QNEXA in the EU

VIVUS seeks marketing approval of QNEXA in the EU

VIVUS submits briefing document to FDA in effort to secure regulatory approval for QNEXA

VIVUS submits briefing document to FDA in effort to secure regulatory approval for QNEXA